*Optimal dilutions/concentrations should be determined by the researcher.
Not tested in other applications.
A431 , H1299 , HeLa , HepG2
Bovine, Pig, Chimpanzee, Rhesus Monkey(>80% identity)
0.1M Tris, 0.1M Glycine, 10% Glycerol (pH7). 0.01% Thimerosal was added as a preservative.
Store as concentrated solution. Centrifuge briefly prior to opening vial. For short-term storage (1-2 weeks), store at 4ºC. For long-term storage, aliquot and store at -20ºC or below. Avoid multiple freeze-thaw cycles.
0.64mg/ml(Please refer to the vial label for the specific concentration.)
Carrier-protein conjugated synthetic peptide encompassing a sequence within the N-terminus region of human mu Opioid receptor. The exact sequence is proprietary.
Purified by antigen-affinity chromatography.
For laboratory use only. Not for any clinical, therapeutic, or diagnostic use in humans or animals. Not for animal or human consumption.
KIAA0403 antibody, LMOR antibody, MOR antibody, MOR1 antibody, OPRM antibody, OPRM1 antibody, mu opioid receptor splice variant hMOR-1b antibody, mu opiate receptor antibody, hMOP antibody, MOP antibody, M-OR-1 antibody, mu-type opioid receptor antibody, "opioid receptor, mu 1 antibody"
The OPRM1 gene encodes the mu opioid receptor, which is the primary site of action for the most commonly used opioids, including morphine, heroin, fentanyl, and methadone. It is also the primary receptor for endogenous opioid peptides beta-endorphin (see POMC, MIM 176830) and the enkephalins (see PENK, MIM 131330). The OPRM1 receptor is a membrane of the G protein-coupled receptor family (Bond et al., 1998 [PubMed 9689128]). There are at least 3 types of opioid receptors, mu, kappa (OPRK1; MIM 165196), and delta (OPRD1; MIM 165195), each with a distinct pharmacologic profile (Chen et al., 1993 [PubMed 8393525]).[supplied by OMIM]